NeoGenomics Inc (NEO) - Total Assets
Based on the latest financial reports, NeoGenomics Inc (NEO) holds total assets worth $1.35 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check NEO capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
NeoGenomics Inc - Total Assets Trend (2000–2025)
This chart illustrates how NeoGenomics Inc's total assets have evolved over time, based on quarterly financial data. Explore NeoGenomics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
NeoGenomics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
NeoGenomics Inc's total assets of $1.35 Billion consist of 27.7% current assets and 72.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.7% |
| Accounts Receivable | $159.24 Million | 11.7% |
| Inventory | $28.57 Million | 2.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $286.53 Million | 21.1% |
| Goodwill | $524.34 Million | 38.6% |
Asset Composition Trend (2000–2025)
This chart illustrates how NeoGenomics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NEO market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NeoGenomics Inc's current assets represent 27.7% of total assets in 2025, a decrease from 100.0% in 2000.
- Cash Position: Cash and equivalents constituted 11.7% of total assets in 2025, down from 100.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 59.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 38.6% of total assets.
NeoGenomics Inc Competitors by Total Assets
Key competitors of NeoGenomics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.33 Billion |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716
|
China | CN¥1.74 Billion |
|
Spectral Med Inc
TO:EDT
|
Canada | CA$8.12 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Genetic Signatures Ltd
AU:GSS
|
Australia | AU$49.04 Million |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
Germany | €13.12 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
NeoGenomics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.42 | 2.05 | 7.28 |
| Quick Ratio | 4.06 | 1.95 | 7.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $289.09 Million | $294.24 Million | $622.66 Million |
NeoGenomics Inc - Advanced Valuation Insights
This section examines the relationship between NeoGenomics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.41 |
| Latest Market Cap to Assets Ratio | 0.83 |
| Asset Growth Rate (YoY) | -17.0% |
| Total Assets | $1.36 Billion |
| Market Capitalization | $1.13 Billion USD |
Valuation Analysis
Near Book Valuation: The market values NeoGenomics Inc's assets close to their book value (0.83x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: NeoGenomics Inc's assets decreased by 17.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NeoGenomics Inc (2000–2025)
The table below shows the annual total assets of NeoGenomics Inc from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.36 Billion | -16.98% |
| 2024-12-31 | $1.64 Billion | -2.57% |
| 2023-12-31 | $1.68 Billion | -3.38% |
| 2022-12-31 | $1.74 Billion | -6.94% |
| 2021-12-31 | $1.87 Billion | +89.19% |
| 2020-12-31 | $988.33 Million | +39.30% |
| 2019-12-31 | $709.51 Million | +40.49% |
| 2018-12-31 | $505.01 Million | +47.09% |
| 2017-12-31 | $343.34 Million | +1.85% |
| 2016-12-31 | $337.12 Million | -8.38% |
| 2015-12-31 | $367.95 Million | +353.67% |
| 2014-12-31 | $81.11 Million | +103.19% |
| 2013-12-31 | $39.92 Million | +32.74% |
| 2012-12-31 | $30.07 Million | +50.74% |
| 2011-12-31 | $19.95 Million | +46.14% |
| 2010-12-31 | $13.65 Million | +5.45% |
| 2009-12-31 | $12.95 Million | +77.45% |
| 2008-12-31 | $7.30 Million | +11.88% |
| 2007-12-31 | $6.52 Million | +108.21% |
| 2006-12-31 | $3.13 Million | +189.97% |
| 2005-12-31 | $1.08 Million | +82.45% |
| 2004-12-31 | $592.00K | +16.76% |
| 2003-12-31 | $507.04K | +13.22% |
| 2002-12-31 | $447.84K | +450.56% |
| 2001-12-31 | $81.34K | +43632.80% |
| 2000-12-31 | $186.00 | -- |
About NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to dise… Read more